Close Menu

NEW YORK – Danaher subsidiary Beckman Coulter announced on Tuesday that its Access SARS-CoV-2 IgG II antibody test has received Emergency Use Authorization from the US Food and Drug Administration.

The test measures IgG antibodies to SARS-CoV-2 in the receptor-binding domain of the spike protein of the virus from plasma and has demonstrated 99.9 percent specificity and 98.9 percent sensitivity at 15 to 60 days after symptom onset, according to a statement from the company. The semi-quantitative assay provides a qualitative and numerical result of antibodies in arbitrary units.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.